Direct compression of 2-(3-chloropropyl)-2,5,5-trimethyl-[1,3]-dioxane onto a rotary tablet press is selected only after the API lot has been screened through a 500 µm mesh and blended into a moisture-buffering filler matrix. The acetal ring and the terminal chloropropyl group require that the micro-environmental pH within the tablet remain above 5.0; formulations therefore avoid anhydrous acidic excipients such as dibasic calcium phosphate at high loadings and rely instead on microcrystalline cellulose at 30–60% w/w, lactose monohydrate at 20–50% w/w, croscarmellose sodium at 2–5% w/w, and magnesium stearate at 0.25–1.0% w/w. The API is pre-blended with an equal mass of lactose monohydrate for 10 min in a 150 L bin blender at 12 rpm, then the remaining excipients are added and blended for an additional 15 min; lubricant is added last for 3 min to avoid over-lubrication. On a 10–27 kN compression force, tablet hardness is maintained between 50 N and 110 N, and friability is held at ≤1.0% per USP <1216>. The compressed tablet must meet blend uniformity acceptance of RSD ≤5.0% under USP <905> and dissolution Q=75% at 45 min under USP <711>. The end product is an immediate-release tablet packaged in high-density polyethylene bottles with silica gel desiccant and induction-sealed closures to keep equilibrium moisture below 2.0% w/w.

In capsule filling, the low bulk density of a micronized API fraction can generate weight variation if the powder is not densified before encapsulation; the formulation therefore uses a dry preblend of API at 5% w/w with spray-dried lactose monohydrate at 60–80% w/w, pregelatinized starch at 15–25% w/w, and colloidal silicon dioxide at 0.5–2.0% w/w. The preblend is passed through an 800 µm conical mill, blended in a 300 L bin blender at 10 rpm for 20 min, and filled into size 3 hard gelatin capsules at a target fill weight of 220–250 mg using a dosator-type capsule filling machine operating at 30,000–50,000 capsules/h. Fill weight variation is monitored every 15 min with acceptance of RSD ≤3.5%; capsule disintegration is controlled under USP <701> to ≤15 min in 0.1 N hydrochloric acid, or in pharmacopoeial water if the acetal ring shows acid-catalysed degradation during method development. Hard gelatin capsule shells are stored at 40–50% RH and 15–25°C before filling because shell moisture above 16% w/w can increase local water activity at the API interface. The terminal packaged form is a hard gelatin capsule in cold-form aluminium blister packs with a desiccant pouch, preserving moisture below 3.0% w/w and protecting the acetal ring from humidity-induced hydrolysis during storage.

Wet Granulation Limits for a Hydrolytically Sensitive Chloropropyl Dioxane Derivative

For wet granulation, the 1,3-dioxane ring imposes a pH boundary above 5.5 in the granulating fluid because acidified binder solutions accelerate acetal hydrolysis to 4-chlorobutanal. The binder is prepared as a 3–5% w/w hypromellose E5 solution in purified water, and the aqueous phase is pre-adjusted to pH 5.5–6.5 with 1 N sodium hydroxide before addition. Granulation is performed in a high-shear mixer with an impeller speed of 300–500 rpm, a chopper at 1500–3000 rpm, and a granulation time of 2–5 min; the dry powder charge contains API at 2–10% w/w, lactose monohydrate at 40–70% w/w, microcrystalline cellulose at 20–40% w/w, and croscarmellose sodium at 2–5% w/w as intragranular disintegrant. The wet mass is dried in a fluidised-bed dryer with an inlet air temperature of 50–65°C and product temperature maintained below 40°C to prevent thermal degradation; endpoint is obtained at a loss on drying of 1.5–2.5% w/w. Dried granules are milled through a 1.0 mm screen, and extragranular crospovidone at 2–5% w/w plus magnesium stearate at 0.5% w/w are added before compression or sachet filling. The terminal product is a granule intermediate for immediate-release tablets or oral unit-dose sachets; if sachets are filled, fill weight variation is controlled at RSD ≤2.0% and water activity is specified at ≤0.6 a_w.

When the API Must Be Delivered as a Sterile Solution, Aseptic Filtration Replaces Terminal Steam Cycles

When an injectable solution of the API is required and the acetal ring is unstable under the time–temperature load of terminal steam sterilisation, the manufacturing route shifts to aseptic filtration. The solution is prepared in Water for Injection that has been sparged with nitrogen to reduce dissolved oxygen, and the pH is maintained at 5.5–6.5 with 10–50 mM citrate or phosphate buffer; this pH window retards acid-catalysed hydrolytic opening of the dioxane ring while avoiding excessive nucleophilic hydroxide exposure. Osmolality is adjusted with sodium chloride or mannitol to 270–320 mOsm/kg as measured by freezing-point depression according to USP <785>. The solution is passed through a prefilter with a 0.45 µm PVDF membrane and then sterilised by filtration through two 0.22 µm PVDF or PES membrane filters in series, with filter compatibility and bacterial retention validation reflecting ASTM F838-20 or equivalent. Filled volume is 5.0 mL per single-dose vial, and the headspace is overlayed with nitrogen before stoppering with bromobutyl rubber closures. The finished injection is tested under USP <71> for sterility, USP <85> for bacterial endotoxins with limits calculated from the K/M rule, USP <788> for particulate matter, and USP <790> for visible particulates. The terminal product is a single-dose injectable solution in Type I borosilicate glass vials, stored at 2–8°C in light-protective secondary packaging if photostability data indicate sensitivity.

What Lyophilisation Cycle Parameters Protect the Acetal Ring During Injectable Freeze-Drying?

Freeze-drying is applied when the aqueous stability data for the API show unacceptable degradation in liquid form. The pre-lyophilisation solution is prepared with a bulking agent, typically mannitol at 4–5% w/v, and a lyoprotectant, trehalose dihydrate at 2–5% w/v, both of which produce a crystalline or amorphous matrix that prevents cake collapse. The formulation is filled at 5.0 mL into Type I glass vials, loaded onto a freeze-dryer with a shelf temperature setpoint of -40°C for freezing, and held for 3–5 h to ensure complete solidification. Primary drying is run at a shelf temperature of -25°C and chamber pressure of 50–80 mTorr to maintain product temperature below the verified collapse temperature for the mannitol-trehalose matrix; because published freeze-drying data for this exact molecular entity are limited, the specific collapse temperature is confirmed by freeze-drying microscopy before scale-up. Secondary drying is performed at 25°C for 6–10 h until the cake moisture content measured by Karl Fischer titration under USP <922> is ≤2.0% w/w. The vials are stoppered under vacuum or partial nitrogen and sealed with flip-off caps. Batch release testing includes USP <71>, USP <85>, USP <922>, USP <788>, and residual solvent testing under ICH Q3C where lyophilisation uses organic co-solvents. The terminal product is a lyophilised cake for reconstitution with 5.0 mL Water for Injection to a particle-free solution.

Controlling Residual Moisture in Roller-Compacted Granules for Reconstituted Oral Suspensions

Roller compaction displaces wet granulation for oral suspension granules when the API demonstrates hydrolytic sensitivity above water activity 0.5. The dry blend contains API at 5–15% w/w, microcrystalline cellulose at 60–80% w/w, crospovidone at 2–5% w/w, and sodium stearyl fumarate at 1–2% w/w as the internal lubricant; the blend is pre-compacted on a roller compactor with roll force of 4–10 kN/cm, roll speed of 5–15 rpm, and gap width of 1.5–2.0 mm. Ribbons are milled through a 0.8 mm screen to produce granules with a target size fraction of 0.20–0.71 mm and a fines fraction below 25% w/w. Granule flow is tested using USP <1174> or Ph. Eur. 2.9.36, and water activity is controlled to ≤0.6 by storing the granules in aluminium-lined sachets with desiccant. When the granules are reconstituted with 5.0 mL purified water to form an oral suspension, the dispersant system should include xanthan gum at 0.2–0.5% w/w in the granule formulation or a separately packed diluent; because the acetal ring is acid-sensitive, the reconstituted suspension is buffered to pH 5.5–6.5 and is not held beyond 14 days at 2–8°C unless preservative efficacy has been validated under USP <51>. The terminal product is a granule-filled sachet or bottle for oral suspension, with microbial quality acceptance under USP <1111> for non-sterile aqueous oral products and dissolution of the reconstituted suspension evaluated under USP <711> where the dosage form is a suspension.